After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing ...

September is World Alzheimer's Month and this year’s theme is “Time to act on dementia, time to act on Alzheimer’s." ...

In Alzheimer’s disease (AD), significant numbers of nerve cells in the brain die, affecting patients’ ability to remember things and to think clearly — resulting in confusion, behavioral changes and ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

Alzheimer’s disease is the most common cause of dementia, affecting millions of mostly elderly people around the world. In these people, the synaptic activity (connections between nerve cells) ...

A reader's comment prompts columnist Ray Burow to reinforce the purpose of her column: providing hope to those with an Alzheimer's diagnosis.

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...